[Federal Register Volume 79, Number 72 (Tuesday, April 15, 2014)]
[Notices]
[Pages 21251-21252]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-08387]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Option License: Immunotherapy 
Vaccine for Treating Lymphoma and Leukemia

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant to University of Texas 
MD Anderson Cancer Center, of an exclusive option license to practice 
the inventions embodied in the following US Patents and US Patent 
Applications (and all foreign counterparts) for the continued research 
and development of the inventions: US Patent Application Serial No. 13/
890,502, entitled, ``Viral Chemokine-antigen Fusion Proteins'' [HHS 
Ref. No. E-194-2000/0-US-06] and in US Patent Serial No. 8,258,278 and 
US Patent Application Serial No.13/587,515, both entitled ``Methods and 
Compositions for the Treatment and Prevention of Cancer'' [HHS Ref. 
Nos. E-271-2006/0-US-03 and E-271-2006/0-US-04, respectively]. The 
patent rights in this invention have been assigned to the Government of 
the United States of America.
    The exclusive option license may be term-limited, the prospective 
territory may be worldwide, and the field of use may be limited to:

    Research, development, manufacture, and related non-commercial 
use in humans for the treatment of B-cell leukemias and B-cell 
lymphoma of a chemokine-tumor antigen fusion protein in which the 
chemokine is viral Macrophage Inflammatory Protein 3 Alpha 
(MIP3[alpha]) and the tumor antigen is the epitope of a malignant B-
cell immunoglobulin idiotype of an antibody produced by a B-cell 
lymphoma.

Prior to the expiration or termination of the exclusive option license, 
University of Texas M.D. Anderson Cancer Center will have the exclusive 
right to amend the option license to include the right to sublicense 
for commercialization.

DATES: Only written comments or applications for a license (or both) 
which are received by the NIH Office of Technology Transfer on or 
before April 30, 2014 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments, and other materials relating to the contemplated exclusive 
option license should be directed to: Yolanda Mock Hawkins, Ph.D., 
M.B.A., Licensing and Patenting Manager, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-5170; Facsimile: (301) 
402-0220; Email: [email protected].

SUPPLEMENTARY INFORMATION: This invention concerns a cancer treatment 
for B-cell lymphoma comprising a vaccine that increases the ability of 
a B-cell lymphoma antigen to provoke an immune response in the body. In 
particular, the vaccine comprises a viral chemokine fused to a tumor 
antigen and

[[Page 21252]]

is administered as either a protein or a nucleic acid.
    The prospective exclusive option license, and any potential 
sublicense, will comply with the terms and conditions of 35 U.S.C. 209 
and 37 CFR part 404. The prospective exclusive option license, may be 
granted unless the NIH receives within fifteen (15) days from the date 
of this published notice written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive option license. Comments and objections 
submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: April 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-08387 Filed 4-14-14; 8:45 am]
BILLING CODE 4140-01-P